HIV-1 gp120 Antibody
Description
Product Specs
Product Science Overview
Human Immunodeficiency Virus type 1 (HIV-1) is a retrovirus that causes Acquired Immunodeficiency Syndrome (AIDS). One of the critical components of HIV-1 is the envelope glycoprotein gp120, which plays a crucial role in the virus’s ability to infect host cells. Rabbit antibodies against HIV-1 gp120 have been developed for research purposes to study the virus’s mechanisms and to develop potential treatments and vaccines.
The gp120 protein is a part of the HIV-1 envelope glycoprotein complex, which also includes gp41. These proteins are initially synthesized as a single precursor protein, gp160, which is then cleaved into gp120 and gp41 . The gp120 protein is responsible for binding to the CD4 receptors on the surface of host cells, primarily helper T cells . This binding is the first step in the viral entry process, which is followed by a conformational change in gp120 that allows it to interact with co-receptors CCR5 or CXCR4 .
Rabbit antibodies against HIV-1 gp120 are valuable tools in HIV research. These antibodies are generated by immunizing rabbits with recombinant gp120 protein, leading to the production of monoclonal antibodies that can specifically recognize and bind to gp120 . Rabbit antibodies are known for their high affinity and specificity, making them ideal for various applications, including:
- Neutralization assays: To test the ability of antibodies to prevent HIV-1 from infecting host cells.
- Epitope mapping: To identify specific regions of gp120 that are recognized by antibodies.
- Vaccine development: To evaluate the immune response generated by potential HIV-1 vaccines.
Rabbit antibodies against HIV-1 gp120 have been used in numerous studies to advance our understanding of HIV-1 and to develop new therapeutic strategies. For example, a large panel of rabbit monoclonal antibodies was characterized to identify novel neutralizing antibodies against the V3 loop of gp120 . These studies have provided insights into the mechanisms of viral entry and the potential for developing broadly neutralizing antibodies that can target multiple HIV-1 strains.
